Figure 1From: Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response(a) Progression-free survival; (b) Overall survival of patients in the phase II study.Back to article page